Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection.

Next Previous
Trial Profile

A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ledipasvir (Primary) ; Vedroprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Tegobuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences

Most Recent Events

  • 05 Feb 2014 Results published in Hepatology.
  • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 18 Apr 2012 Interim safety and efficacy data will be presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL), according to a Gilead Sciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top